Clinical Trials Directory

A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML

This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : 5-Azacitidine
  • drug : Gemtuzumab ozogamicin

Phase: Phase 1/Phase 2


Ages Eligible For Study:

18 Years - 90 Years

Inclusion Criteria

- Diagnosis of Relapsed AML - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy > 3 months - ? 18 years old - Previously untreated for current AML relapse - Adequate organ function - Written informed consent

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting

Footer Links: